STS 2025

STS 2025

STS 2025

Advertisement

The STS General Thoracic Surgery Database: Task Force Chair Shares Insights, Updates

Christopher Seder, MDSTS 2025 | February 14, 2025

Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...

The Future of Surgery for Stage IV Lung Cancer: Dr. Antonoff Shares Hopes, Insights

Mara B. Antonoff, MD, FACSSTS 2025 | February 11, 2025

Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.

Sublobar Resection Versus Lobectomy: Dr. Seder Discusses Real-World Outcomes in Early-Stage NSCLC

Christopher Seder, MDSTS 2025 | January 31, 2025

Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.

Surgery for Stage IV Lung Cancer: Dr. Antonoff Shares Insights From STS 2025 Session

Mara B. Antonoff, MD, FACSSTS 2025 | January 28, 2025

Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.

Real-World Study: Lobectomy Linked With Higher OS Rates Than Wedge Resection in Early-Stage NSCLC

Cecilia BrownSTS 2025 | January 27, 2025

However, the study findings presented at STS 2025 suggest that segmentectomy may be a “viable alternative” to lobectomy.

Advertisement

Advertisement

Advertisement

Latest News

HARMONi-2 Interim Analysis: Ivonescimab Shows PFS Improvements Over Pembrolizumab in NSCLC

March 7, 2025

Stephen Liu, MD, on Key Debates in NSCLC

March 7, 2025

How Frequent Is Suture-Line Recurrence After Surgery for Early-Stage NSCLC?

March 5, 2025

CROWN 5-Year Subgroup Analysis Shows PFS Is Consistent With Overall Patient Population

March 5, 2025

Can Systematic Immune Inflammation Predict Survival in Patients Receiving Immune Checkpoint Inhibitors for NSCLC?

March 5, 2025

LUPER Study Evaluates Lurbinectedin Plus Pembrolizumab in Relapsed SCLC

March 5, 2025